Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06801626 · ClinicalTrials.gov registry record · Phase 3
Novel Strategies for Reducing Burn Scar Itch
A Phase 3 study of Wound and Burn Scar, sponsored by The University of Texas Medical Branch, Galveston.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT06801626: Recruiting Phase 3 study of Wound and Burn Scar, sponsored by The University of Texas Medical Branch, Galveston.
NCT06801626 is a Phase 3 study of Wound and Burn Scar that is actively recruiting participants, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 44 participants, below the 420-participant average among 8 other Wound trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06801626, a Phase 3 study of Wound and Burn Scar, is actively recruiting participants, sponsored by The University of Texas Medical Branch, Galveston.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to see whether using diphenhydramine (Benadryl), famotidine (Pepcid), and cromolyn sodium will decrease burn scar itch.
Primary Outcome
Patients will score the severity of itch on the scale provided at study start, once weekly for 3 months, at the 3-month visit, and again at study end (6 months). Patients will rate their itch from 0 to 10. to measure the intensity of itchiness, where a patient marks a point on a line to indicate how severe their itch is, with zero representing "no itch" and 10 representing "worst imaginable itch." A higher score means a worse outcome.
Conditions Studied
Interventions
- OTHER Placebo
- COMBINATION_PRODUCT Famotidine and 4% topical cromolyn sodium
Study Locations (1)
Texas
- University of Texas Medical Branch, Galveston - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2025-03-01 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 3 |
What NCT06801626 shows while recruiting
NCT06801626 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 420-participant average among 8 other Wound trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Wound appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06801626 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06801626 about?
NCT06801626 is a clinical study titled "Novel Strategies for Reducing Burn Scar Itch". The purpose of the study is to see whether using diphenhydramine (Benadryl), famotidine (Pepcid), and cromolyn sodium will decrease burn scar itch.
What is the current status of trial NCT06801626?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2025-03-01. Estimated completion is 2027-11-01.
What conditions does trial NCT06801626 study?
This clinical trial studies the following conditions: Wound, Burn Scar, Itch Scarring.
What interventions are being tested in trial NCT06801626?
The interventions under investigation include: Placebo (OTHER), Famotidine and 4% topical cromolyn sodium (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06801626?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06801626 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wound
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06801626's enrollment target sits among peer trials
44 7th of 8 higher than 1 of 8 other Wound trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Wound trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tissue Repair Gel in Venous Leg Ulcers in AU/US
RECRUITING · Phase 3
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Miro3D Randomized Controlled Trial (RCT)
RECRUITING · NA
-
A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing
RECRUITING · NA
-
Wound Healing Endpoint and Recurrence
ACTIVE NOT RECRUITING · Phase 1
-
Geko™ Cross Therapy Registry - Wound
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI